The market for private-label OTC drugs is expected to reach $3.6 billion by 2010, according to a new study by Kalorama Information, a division of MarketResearch.com. The study found that private-label brands ate up 19.7% of the OTC market share in 2004, with sales topping $3.4 billion in 2005.
Private-label OTCs making a dent in brand-name share
The market for private-label OTC drugs is expected to reach $3.6 billion by 2010, according to a new study by Kalorama Information, a division of http://MarketResearch.com/. The study found that private-label brands ate up 19.7% of the OTC market share in 2004, with sales topping $3.4 billion in 2005. The market was buoyed by growing sales in the cough, cold, allergy, sinus, first-aid, and antismoking sectors.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
2 Commerce Drive
Cranbury, NJ 08512